Recruiting

WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt

The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).

I'm interested View official listing

ClinicalTrials.gov IDNCT05183230

PhaseNA

Enrollment115

SponsorWeill Medical College of Cornell University

Age50 Years – 90 Years

SexALL

I'm interested View official listing

Conditions studied

Suicide, Attempted, Suicidal Ideation, Depression

About this study

Interventions

Behavioral: WellPATH-PREVENT — WellPATH-PREVENT is a novel personalized, easy to use, mainly stand-alone mobile intervention which focuses on the exclusive use of the WellPATH tablet app and includes training meetings during hospitalization, and virtual post-discharge coaching meetings. The meetings aim to: a) identify stressors and triggers of negative emotions associated with increased suicidal ideation or with suicidal behavior; b) develop techniques (text or video) to increase cognitive reappraisal ability; c) incorporate the techniques into the WellPATH app and promote the use of WellPATH during stressful incidents, triggers of negative emotions, or scheduled brief training sessions; and d) remotely update the triggers, negative emotions, and techniques in the app.
Behavioral: Optimized WellPATH-PREVENT — The Optimized WellPATH-PREVENT intervention will be as described above, but based on the results of the Proof-of-Concept (R61) Phase, an expert committee will help select the duration (6 or 12 weeks) that shows greater improvement in cognitive reappraisal.

Primary outcomes

Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R61 (Study Entry, Week 6, Week 12)
Change in Event Related Potential - Late Positive Potential (ERP/LPP) - R33 (Study Entry, Week 6, Week 12, Week 24)
Change in Self-Reported Affect - R61 (Study Entry, Week 6, Week 12)
Change in Self-Reported Affect - R33 (Study Entry, Week 6, Week 12, Week 24)
Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R61 (Study Entry, Week 6, Week 12)
Change in Emotion Regulation (Cognitive Reappraisal Subscale of ER Questionnaire) - R33 (Study Entry, Week 6, Week 12, Week 24)
Change in Client Satisfaction with Treatment (CSQ) - R61 (Week 6, Week 12)
Change in Client Satisfaction with Treatment (CSQ) - R33 (Week 6, Week 12, Week 24)

Eligibility information

Inclusion Criteria: * 50-90 years old * Diagnosis (based on a modified SCID-5 Clinical Trials Version to assess DSM-5 diagnoses): Any DSM-5 except: current diagnosis of Psychotic Disorder; diagnosis of Dementia * Recent hospitalization for suicidal ideation or suicide attempt; at hospital admission, Columbia Suicide Severity Rating Scale (CSSR-S) ≥ 2, "Non-specific Active Suicidal Thoughts." * We will also include patients on psychotropics and on after-care community psychotherapy. Exclusion Criteria: * Current diagnosis of Psychotic Disorders; Diagnosis of Dementia * Cognitive Impairment (MMSE ≤ 24) * Acute or severe medical illness (i.e., delirium; decompensated cardiac, liver or kidney failure; major surgery; stroke or myocardial infarction during the three months prior to entry * Aphasia, sensory problems, and/or inability to speak English.

Study locations

New York Presbyterian Hospital/Weill Cornell Medicine, New York, New York 10065 United States
Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York 10605 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-28.